Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • krobison
    Senior Member
    • Nov 2007
    • 734

    #1

    How do variant callers deal with overlapping paired end reads?

    Question arising from another thread in the forums; I'm posting this separately (and cross-referencing) because I want to ask the more bioinformatics and less sample-prep oriented subset.

    An apparently property of at least some hybridization capture methods is a tendency to reduce the library size. As a result, with long Illumina reads the paired end reads may overlap in the middle.

    How do the variant callers out there handle this? If a variant is found in the overlap & the two reads agree, then that is clearly stronger evidence that a given variant is present in that DNA fragment. BUT, if you are worried about PCR (or sample damage such as FFPE) artifacts then you may want some separate accounting for having actually seen the same variant in two different fragments.
  • nilshomer
    Nils Homer
    • Nov 2008
    • 1283

    #2
    Originally posted by krobison View Post
    Question arising from another thread in the forums; I'm posting this separately (and cross-referencing) because I want to ask the more bioinformatics and less sample-prep oriented subset.

    An apparently property of at least some hybridization capture methods is a tendency to reduce the library size. As a result, with long Illumina reads the paired end reads may overlap in the middle.

    How do the variant callers out there handle this? If a variant is found in the overlap & the two reads agree, then that is clearly stronger evidence that a given variant is present in that DNA fragment. BUT, if you are worried about PCR (or sample damage such as FFPE) artifacts then you may want some separate accounting for having actually seen the same variant in two different fragments.
    The short answer is it treats both ends as if they were from independent fragments.

    What is more powerful/accurate, having two observations of the same DNA fragment (read pairs overlapping), or two observations of the same haplotype (sampling with two fragment reads)?

    The former may improve the consensus call of the read, but does not increase the number of times an allele is sampled. The latter is independent of sequencing error artifacts from the same fragment and provides an independent observation of the same haplotype. Basically, if you need 30x diploid coverage to guarantee to see both alleles of a heterozygous variant, the former should count only once while the latter should count twice.
    Last edited by nilshomer; 04-30-2010, 11:59 AM. Reason: speak-n-spell

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    10 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    11 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    37 views
    0 reactions
    Last Post SEQadmin2  
    Working...